Predictive and prognostic value of classification by immunohistochemical phenotypes in localised breast cancer treated with dose-dense adriamycin/cyclophosphamide
Journal Title: Journal of Cancer Research & Therapy - Year 2015, Vol 3, Issue 11
Abstract
Introduction: Histopathologic subtyping according to the St. Gallen classification is predictive of response in women with breast cancer treated with neoadjuvant chemotherapy (NCT). Our aim was to confirm its predictive role when dose-dense (DD) chemotherapy is administered. Methods: A prospective study was performed in stage II-III breast cancer treated with four cycles of doxorubicin-cyclophosphamide every two weeks, followed by 4 cycles of docetaxel every 3weeks. Tumours were grouped into 4 subtypes. Simple and multivariate logistic regression analysis was performed to determine the association between pathologic complete response (pCR), according to the Miller & Payne classification and tumour subtype. In addition survival analysis was performed. Results: 71 patients were included. By phenotypic classification, 11.3% were Luminal A, 59.2% Luminal B, 8.5% pure HER2 and 21.1% TN. Following the administration of DD NCT, a pCR rate of 25.4% was achieved. There was a significant association between the pCR rate and the different immune phenotypes (p=0.05). The pCR rate was 46.7% for the TN patients and 19.6% for the others (p=0.046). At 30 months’ followup, the rate of disease-free survival (DFS) was 71.8% for the TN patients and 93.3% for all others. The difference was also significant for overall survival (p=0.006), with 100% of the non-TN patients alive vs 85.7% of the TN patients. Within the TN subtype, the patients who achieved pCR had a better DFS (p=0.04) and a better rate of overall survival. Conclusions: Tumour classification according to the St. Gallen phenotypes is useful in predicting response and survival in breast cancer patients treated with DD neoadjuvant chemotherapy.
Authors and Affiliations
Pedrinaci IZ, Maximino R, Ángel C, Francisco RR, Luis JP, Antonio R
Keywords
Related Articles
- EP ID EP547249
- DOI 10.14312/2052-4994.2015-19
- Views 51
- Downloads 0
With increasing age at tumor diagnosis in familial cancer: Cancer is limited to fewer organs
Hereditary cancer that has monogenic inheritance affects every tenth patient, on average, who is diagnosed with cancer, and it has been suggested, based on twin studies, that approximately 30% of all cancer patients have...
Epifluorescent imaging study of the effect of anti-diabetic drug metformin on colorectal cancer cell lines in vitro
Metformin, a widely used anti-diabetic drug, has recently been associated with inhibition of cell proliferation in multiple cancers. However, it is not clear if the reduction in proliferation on treatment with metformin...
Primary small cell neuroendocrine carcinoma of the breast: a report of two cases and review of the literature
Primary neuroendocrine carcinomas of the breast are extremely rare. Neuroendocrine tumors mainly occur in the broncopolmonary system and gastrointestinal tract. The diagnosis of small cell neuroendocrine carcinoma (SCNC)...
Stem cells’ guided gene therapy of cancer: New frontier in personalized and targeted therapy
Diagnosis and therapy of cancer remain to be the greatest challenges for all physicians working in clinical oncology and molecular medicine. The grim statistics speak for themselves with reports of 1,638,910 men and wome...
Synergistic antineoplastic action of 5-aza-2'deoxycytidine (decitabine) in combination with different inhibitors of enhancer of zeste homolog 2 (EZH2) on human lung carcinoma cells
Patients with metastatic lung cancer have a very poor prognosis indicating an urgent need to develop more effective chemotherapy. Aberrant promoter DNA methylation can result in the epigenetic silencing of tumor suppress...